<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02081287</url>
  </required_header>
  <id_info>
    <org_study_id>DBDAT-2013-MJM</org_study_id>
    <nct_id>NCT02081287</nct_id>
  </id_info>
  <brief_title>Inositol Hexaphosphate: A Novel Treatment Strategy for Bipolar Disorder?</brief_title>
  <official_title>Inositol Hexaphosphate: A Novel Treatment Strategy for Bipolar Disorder?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>San Diego Veterans Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Depressive and Bipolar Disorder Alternative Treatment Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>San Diego Veterans Healthcare System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inositol hexaphosphate (IP6, also called inositol hexakisphosphate, and phytic acid) is a
      naturally occurring phosphorylated derivative of myo-inositol. Myo-inositol has shown
      preliminary evidence of efficacy in controlling mood symptoms, and good tolerability in
      bipolar disorder in some studies, but failed to establish efficacy in subsequent
      meta-analyses. In the investigators proposed work, the investigators plan to orally
      administer the calcium/magnesium salt of IP6 (2,000-3,000 mg daily in two divided doses) to
      paid research subjects with a diagnosis of bipolar disorder who are in a depressed state, and
      who have failed an adequate course of treatment with lithium monotherapy. The investigators
      hypothesis is that IP6 may be similar to myo-inositol in terms of relieving depression, but
      more potent and effective. Our aim is conduct a preliminary pilot study in 30 subjects (15
      treated with IP6, 15 treated with lamotrigine, an active comparator) to assess the efficacy
      and tolerability of IP6 as an adjunctive treatment to lithium, the mood stabilizer most
      commonly used to treat bipolar disorder.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Depression</measure>
    <time_frame>10 weeks</time_frame>
    <description>As measured by rater administered Hamilton depression inventory, and Beck Depression Inventory</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality</measure>
    <time_frame>10 weeks</time_frame>
    <description>As measured by the Pittsburgh Sleep Quality Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Function</measure>
    <time_frame>10 weeks</time_frame>
    <description>As measured by the Clinician Global Inventory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Burden</measure>
    <time_frame>10 weeks</time_frame>
    <description>As measured by standardized inventory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mania</measure>
    <time_frame>10 weeks</time_frame>
    <description>As measured by the Young Mania Scale, and Internal State Scale</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Morning vs Evening Preference</measure>
    <time_frame>10 weeks</time_frame>
    <description>As measured by the Basic language morningness scale</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Bipolar Disorder</condition>
  <condition>Manic Depression</condition>
  <arm_group>
    <arm_group_label>Lamotrigine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>As adjunct to lithium therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IP6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>As adjunct to lithium therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IP6</intervention_name>
    <description>IP6 2,000 -3,000 mg per day given orally in two doses</description>
    <arm_group_label>IP6</arm_group_label>
    <other_name>Inositol Hexaphosphate</other_name>
    <other_name>Phytic Acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamotrigine</intervention_name>
    <description>Dose up to 200 mg per day over 10 weeks</description>
    <arm_group_label>Lamotrigine</arm_group_label>
    <other_name>Lamictal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  must have bipolar disorder

          -  must be currently depressed

          -  must have failed adequate trial of lithium monotherapy

          -  must have shown partial response of depression to lithium

        Exclusion Criteria:

          -  diagnoses of schizophrenia, major depression, or other psychotic disorder

          -  currently pregnant

          -  unstable medical condition

          -  active drug or alcohol dependence

          -  concurrent use of antidepressant or mood stabilizer other than lithium

          -  active suicidal or homicidal ideation

          -  past adverse reaction to lamotrigine or current skin rash (lamotrigine arm only)

          -  history of dietary malabsorption or nutritional deficiency (IP6 arm only)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J. McCarthy, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA San Diego Healthcare, UCSD</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael J McCarthy, MD, PhD</last_name>
    <phone>858-642-1520</phone>
    <email>mmccarthy@ucsd.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>VA San Diego Healthcare System</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael McCarthy</last_name>
      <phone>858-642-1520</phone>
      <email>mmccarthy@ucsd.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2014</study_first_submitted>
  <study_first_submitted_qc>March 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2014</study_first_posted>
  <last_update_submitted>November 19, 2015</last_update_submitted>
  <last_update_submitted_qc>November 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>San Diego Veterans Healthcare System</investigator_affiliation>
    <investigator_full_name>Michael McCarthy</investigator_full_name>
    <investigator_title>Staff Psychiatrist</investigator_title>
  </responsible_party>
  <keyword>Bipolar Disorder</keyword>
  <keyword>Depression</keyword>
  <keyword>Inositol</keyword>
  <keyword>Inositol Hexaphosphate</keyword>
  <keyword>Phytic Acid</keyword>
  <keyword>IP6</keyword>
  <keyword>Lithium</keyword>
  <keyword>Lamotrigine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamotrigine</mesh_term>
    <mesh_term>Anticonvulsants</mesh_term>
    <mesh_term>Inositol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

